Our Value Creation Approach
+60%
growth rate
ARCHIMED is accelerating companies growth rate by more than 60% compared to pre-ARCHIMED performance
Creating long-term value is our goal. We help companies improve at what they already do to build sustainable leaders beyond ARCHIMED’s exit horizon. We hold a strong sense of commitment to our partnering companies.
OUR MEDVALUE APPROACH
Our investment committee and investment team include former operators from the healthcare industries, who actively contribute to creating the long-term business builder mindset at ARCHIMED. Supporting our companies’ business development is far more important to us than optimizing financial engineering or debt leverage. We back our companies’ leadership teams and are available to help in their business development efforts if and when required.
INTERNATIONALIZATION
Healthcare industries are international by nature. Our companies operate in global markets and face global competition. Thanks to ARCHIMED’s international team, presence and experience, we support their internationalization efforts, whether organically or through acquisitions. We help them set up a direct sales force and subsidiaries in the most strategic markets as well as finding distributors elsewhere.
“ARCHIMED’s international expansion expertise and local resources helped us globalize and expand our direct sales, making the US our largest market and significantly contributing to Polyplus‘ growth.”
Gabriel Festoc
Chairman, Polyplus
INTERNATIONALIZATION
Healthcare industries are international by nature. Our companies operate in global markets and face global competition. Thanks to ARCHIMED’s international team, presence and experience, we support their internationalization efforts, whether organically or through acquisitions. We help them set up a direct sales force and subsidiaries in the most strategic markets as well as finding distributors elsewhere.
“ARCHIMED’s international expansion expertise and local resources helped us globalize and expand our direct sales, making the US our largest market and significantly contributing to Polyplus‘ growth.”
Gabriel Festoc
Chairman, Polyplus
INNOVATION
Investing in innovation is key for growth acceleration. At ARCHIMED, we offer a tailored approach for companies. This includes investments in new technology, increasing investment in R&D, support with compliance and accreditation to complete in-house offering.
“ARCHIMED’s investment in innovation gave us a major technology edge, significantly boosting our profit margin in what was otherwise a low-margin, commoditized space.”
Derrick Farrell
CEO, Vita Health Group
INNOVATION
Investing in innovation is key for growth acceleration. At ARCHIMED, we offer a tailored approach for companies. This includes investments in new technology, increasing investment in R&D, support with compliance and accreditation to complete in-house offering.
“ARCHIMED’s investment in innovation gave us a major technology edge, significantly boosting our profit margin in what was otherwise a low-margin, commoditized space.”
Derrick Farrell
CEO, Vita Health Group
BUSINESS DEVELOPMENT
Thanks to our connections with many of the leading companies and key opinion leaders in the industries, including niche sectors, we identify opportunities within the healthcare market. By leveraging this network, we facilitate connections between our companies and prospective clients or business partners to foster synergy and drive innovation.
“ARCHIMED gave us the opportunity to gain real market insight from some of the industry’s most senior people, helping us shape our pricing strategy and become more competitive.”
Lance Burton
CEO, Title21
BUSINESS DEVELOPMENT
Thanks to our connections with many of the leading companies and key opinion leaders in the industries, including niche sectors, we identify opportunities within the healthcare market. By leveraging this network, we facilitate connections between our companies and prospective clients or business partners to foster synergy and drive innovation.
“ARCHIMED gave us the opportunity to gain real market insight from some of the industry’s most senior people, helping us shape our pricing strategy and become more competitive.”
Lance Burton
CEO, Title21
PRODUCT & SERVICE RANGE EXPANSION
By providing the right capital and strategic support, we help our companies accelerate the expansion of their product and service ranges. ARCHIMED consistently increases companies’ R&D budgets compared to the period before partnering with ARCHIMED.
“ARCHIMED has played a crucial role in driving strategic projects within Clean Biologics. Thanks to ARCHIMED, we added viral clearance services to the biosafety testing product portfolio, complementing the offering and reinforcing Clean Cells’ leading position in biosafety testing.”
Joseph Jammal
CEO, Clean Biologics
PRODUCT & SERVICE RANGE EXPANSION
By providing the right capital and strategic support, we help our companies accelerate the expansion of their product and service ranges. ARCHIMED consistently increases companies’ R&D budgets compared to the period before partnering with ARCHIMED.
“ARCHIMED has played a crucial role in driving strategic projects within Clean Biologics. Thanks to ARCHIMED, we added viral clearance services to the biosafety testing product portfolio, complementing the offering and reinforcing Clean Cells’ leading position in biosafety testing.”
Joseph Jammal
CEO, Clean Biologics
M&A AND ADD-ON ACQUISITIONS
ARCHIMED’s network, pipeline, and capabilities are systematically used by our companies to make add-on acquisitions. On average, two acquisitions have been completed by each ARCHIMED company, with some of them completing as many as fifteen.
“Our partnership with ARCHIMED gave us greater freedom to pursue acquisitions and geographical expansion. ARCHIMED’s industry connections and expertise were key components in realizing 15 acquisitions in 3 years.”
Marco Ruini
CEO, BOMI
M&A AND ADD-ON ACQUISITIONS
ARCHIMED’s network, pipeline, and capabilities are systematically used by our companies to make add-on acquisitions. On average, two acquisitions have been completed by each ARCHIMED company, with some of them completing as many as fifteen.
“Our partnership with ARCHIMED gave us greater freedom to pursue acquisitions and geographical expansion. ARCHIMED’s industry connections and expertise were key components in realizing 15 acquisitions in 3 years.”
Marco Ruini
CEO, BOMI
OUR APPROACH TO SUSTAINABILITY
ARCHIMED helps companies advance on their ESG and impact initiatives and enhance their societal contributions, which in turn adds to their intrinsic value. All our companies are assessed through a deep dive Sustainability Assessment which involves our Sustainability and Impact team, the company’s management and where necessary, support from a third-party expert. Based on this assessment, a Sustainability Roadmap with specific KPIs is created, approved at company’s board level and monitored through annual follow-up reviews.
